Drugs / FXS887
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07345637 | Jan 2026 → Apr 2027 expected | refractory malignant neoplasm | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FXS887 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07345637 ↗ |
| Route | Oral | “Eligible subjects will receive oral FXS887 once daily.” NCT07345637 ↗ |